To evaluate the efficacy of intavitreal injection of bevacizumab in patients with chronic central serous chorioretinopathy.

In a clinical interventional case series , 22 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 3 months received intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2 months after the injection. The visual acuity,central macular thickness , Subretinal space volume(SSV) and Contrast sensitivity were compared before and after treatment.

Mean best corrected visual acuity (BCVA) was improved significantly (p = 0.000) from 0.70 ± 0.22 to 0.19 ± 0.24 LogMAR. Central macular thickness was decreased significantly (p = 0.000) from 557.36± 129.12 to 259.50 ± 116.73 µm. Subretinal space volume was decreased significantly (p = 0.03) from 10.53 ± 2.03 to 6.63 ± 1.80. Contrast sensitivity was also increased significantly (p = 0.000) from 2.64820± 13.8182 decibel (dB) to 1.80967 ± 17.6818 dB at last follow-up

Intravitreal bevacizumab can be an alternative treatment in patients with chronic central serous chorioretinopathy as it leads to a better objective visual acuity, contrast sensitivity and foveal thickness.